48 hours from BAA signature to patient enrollment — under your brand, on your subdomain.

Care coordination platform vendors typically quote 6-9 months from contract to first patient enrollment. KLAS Research summaries of CCBHC/FQHC implementations consistently show timelines compounded by serialized legal review, sequential infrastructure stand-up, branding upcharge cycles, and integration work treated as gating rather than parallelizable. The pattern is the same across vendor categories — 30-90 days for BAA execution, 30-60 days for environment provisioning, 60-90 days for branding configuration in enterprise tiers, and 60-120 days for clinical instrument encoding and resource directory verification. Each phase waits on the previous because the vendor architecture treats them as sequential. Clinical directors absorb the timeline as inevitable. It is not.

Cost when unaddressed: Months of clinical opportunity cost — patients fall between systems while a tenant waits for its branded portal to come online.

Incumbent care-coordination platforms surface vendor branding to patients by default. White-labeling is gated behind enterprise tier upcharges or post-launch phase work. Care coordinators field patient questions about a vendor logo they do not recognize while trying to drive completion of a referral the patient is already ambivalent about. The trust hit compounds because the patient experiences the platform as a third-party intermediary rather than as an extension of the clinic they already trust. Brand mismatch on the patient screen reads as institutional confusion, and institutional confusion in behavioral health surfaces as drop-off — measured in completed appointments that never happen.

Cost when unaddressed: Patient trust hits whenever the brand on the screen does not match the clinic the patient just walked out of.

HHS Omnibus Rule (2013) made the Business Associate Agreement contractually binding for any vendor handling PHI on a covered entity's behalf. In practice the BAA execution timeline averages 30-90 days because incumbent vendors treat each red-line as a bespoke negotiation rather than a published-and-versioned legal artifact. HIMSS surveys confirm BAA legal cycle time is the single largest non-technical deploy delay.

Cost when unaddressed: Legal-team capacity gets consumed by line-by-line PHI clause negotiation that should be a one-time platform-wide agreement.

Custom-build paths require clinical engineering teams to encode each validated assessment instrument (PHQ-9, C-SSRS, KDQOL-36, Zarit Burden, ISEL-12, WEMWBS, PRAPARE 10-domain SDOH) from primary literature, validate scoring logic, and re-test on every release. This is months of work duplicated across every tenant build. Each instrument has its own validation chain, its own scoring brackets, its own branching logic, and its own published primary-source citation. C-SSRS branches differ across pediatric, adolescent, and adult versions. PHQ-9 scoring has a discrete suicidality flag that triggers escalation logic. KDQOL-36 has CMS-mandated reporting brackets specific to dialysis. Replicating this work tenant-side is engineering cost without engineering value.

Cost when unaddressed: Clinical-engineering hours that should be spent on workflow design instead get burned on PHQ-9 scoring brackets and C-SSRS branching logic.

Closed-loop SDOH workflows require a verified, insurance-aware community resource directory. ODPHP's Healthy People 2030 SDOH framework calls for measurable community-resource matching, but each tenant build typically restarts directory verification from zero because resource state (open hours, eligibility rules, capacity, accepted insurance) drifts weekly. A community resource that closed three months ago looks identical in a stale directory to one that just doubled its capacity — and the care coordinator only finds out which is which when the patient calls back to say the referral did not work. The directory verification problem is a labor problem, not an architecture problem, and labor has to be amortized across many tenants to be sustainable.

Cost when unaddressed: Care coordinators send referrals into resources that closed last quarter, hit capacity caps, or never accepted the patient's insurance.

OCR's 2024 HIPAA enforcement statistics show that the majority of finalized covered-entity penalties trace to gaps in business associate documentation — not encryption failures. Many vendors verbally assert subprocessor BAA coverage (AWS, cloud AI, database hosting) without publishing the executed chain. When OCR audits the covered entity, the covered entity is on the hook to produce sub-vendor BAAs even though the platform vendor was the one who selected those subprocessors. Compliance officers then spend audit cycles reconstructing chains that should have been published once and dated. The risk surface is documentation, not technology — but the documentation gap is what triggers the finding.

Cost when unaddressed: Compliance team has to reconstruct the BAA chain themselves from vendor security questionnaires that are months stale.

Incumbent care-coordination vendors route post-deploy clinical questions through tier-1 generalist support, escalate to tier-2 implementation specialists, and only reach the engineering team via tier-3 after multi-day SLAs. Clinical directors cannot afford that latency on a workflow question that is blocking a discharge. The escalation tree exists because the vendor needs to gate engineering capacity, not because clinicians need to talk to non-engineers first. The cost is borne by the clinical director who waits two business days for a tier-3 callback to confirm whether a workflow change is feasible. Pilot decisions get made on the basis of what the vendor support tier can answer, not what the platform can do.

Cost when unaddressed: Ticket queue cycle time becomes the rate-limiter on every workflow change a clinical director wants to make post-deploy.

Standard health-IT contracts include multi-year minimums and data-export gates. Tenants who try a vendor for one pilot end up locked into a three-year contract with referral data treated as the vendor's product rather than the clinic's. Exit terms typically require advance notice, written cause, and proprietary-format export through a paid services engagement. The result is that clinical leadership avoids piloting promising tools because exit cost is non-trivial — and the tools that win are not necessarily the tools that perform best, but the ones that lock in the fastest. Standard-format export and no-minimum contract structure flip the incentive: the platform earns the contract every month or it loses it.

Cost when unaddressed: Clinical leadership avoids piloting promising tools because exit cost is non-trivial.